Our results indicate that increased CaM content is a distinct feature of AD, since it was not observed in cells derived from patients with FTD, carriers of the PGRN mutation c.709-1G > A, DLB, PD, ALS or PSP even considering that cell cycle disturbances had been also described in cells from patients of FTD with PGRN mutations [38] and in other neurodegenerative diseases [37]. This evidence concerns the gene GRN and Alzheimer disease.